Assays to predict the clinical significance of blood group antibodies

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 412-416

  Zupańska, Barbara ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY; FC RECEPTOR; RHESUS ANTIGEN; RHESUS D ANTIBODY;

ANTIBODY DETECTION; BIOASSAY; BLOOD TRANSFUSION; CELL MEDIATED CYTOTOXICITY; CHEMOLUMINESCENCE; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; MONOCYTE; NEWBORN HEMOLYTIC DISEASE; PRIORITY JOURNAL; REVIEW; SEROLOGY;

EID: 0031744228     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00010     Document Type: Review

References (43)

1. Urbaniak SJ, Greiss MA, Crawford RJ: Prediction of the outcome of rhesus haemolytic disease of the newborn: additional information using an ADCC assay. Vox Sang 1984, 46:323-329.
2. Nance SJ, Nelson JM, Horenstein J, Garratty G: Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 1989, 92:89-92.
3. Garratty G: Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus Med Rev 1990, 4:297-312.
4. Żupańska B: Clinical application of functional assays for assessing the red cell antibody activity. Transfus Sci 1993, 14:371-381.
5. Żupańska B: Cellular immunoassays and their use for predicting the clinical significance of antibodies. In: Immunobiology of transfusion medicine. Edited by Garratty G. Marcel Dekker, Inc. 1994;465-92.
6. Engelfriet CP, Overbeeke MAM, Dooren MC, Ouwehand WH, von dem Borne AEGKr: Bioassays to determine the clinical significance of red cell alloantibodies based on Fc receptor-induced destruction of red cells sensitized by IgG. Transfusion 1994, 34:617-626.
7. Hadley AG: In vitro assays to predict the severity of hemolytic disease of the newborn. Transfus Med Rev 1995, 4:302-313.
8. Smacchia C, Rebulla P, Drago F, Morelati F, Pappalettera M, Sirchia G: A micro colorimetric assay using cryopreserved monocytes to evaluate antibody-mediated red cell-monocyte interaction. Haematologica 1997, 82:526-531. This technique allows modifying the MMA so that it becomes rapid, reproducible, without the necessity of counting the cells in the microscope.
9. Cassens U, Garritsen HS, Sibrowski W, Holzgreve W: Functional evaluation of erythrocyte antibodies by photometric detection of erythrophagocytosis in the monocyte monolayer assay. Geburtshilfe Frauenheilkd 1996, 56:297-300.
10. Żupańska B, Thompson E, Brojer E, Merry AH: Phagocytosis of erythrocytes sensitized with known amount of IgG1 and IgG3 anti-Rh antibodies. Vox Sang 1987, 53:96-101.
11. van der Winkel JGJ, Anderson CL: Biology of human immunoglobulin G Fc receptors. J Leuk Biol 1991, 49:511-524.
12. Żupańska B, Thomson E, Merry AH: Fc receptors for IgG1 and IgG3 on human mononuclear cells; an evaluation with known levels of erythrocyte-bound IgG. Vox Sang 1986, 50:97-103.
13. Wiener E, Atwal A, Thompson KM, et al: Differences between the activities of human monoclonal IgG1 and IgG3 subclasses of anti-D (Rh) antibody in their ability to mediate red-cell-bindings to macrophages. Immunology 1988, 62:401-404.
14. Brojer E, Merry AH, Żupańska B: Rate of interaction of IgG1 and IgG3 sensitized red cells with monocytes in the phagocytosis assay. Vox Sang 1989, 56:101.
15. Hadley AG, Kumpel BM: Synergistic effect of blending IgG1 and IgG3 monoclonal anti-D in promoting the metabolic response of monocytes to sensitized red cells. Immunology 1989, 67:550.
16. Warmerdam PA, van der Winkel JG, Vlug A, Westerdaal NA: A single aminoacid in the second Ig-like domain of human Fc receptor II is critical for human IgG2 binding. J Immunol 1991, 147:1338-1343.
17. Kumpel BM: In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D. Vox Sang 1997, 72:45-51. The author has demonstrated a functional dichotomy between IgG1 and IgG3 anti-D. Red cells coated by IgG3 were lysed preferentially by monocytes, whereas IgG1-coated by K cells.
18. Kumpel BM, van de Winkel JGJ, Westerdaal NAC, Hadley AG, Dugoujon JM, Blancher A: Antigen topography is critical for interaction of IgG2 anti-red-cell antibodies with Fc receptors. Br J Haematol 1996, 94:175-183.
19. Żupańska B, Brojer E, Richards Y, Seyfried H, Howell P: Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn. Vox Sang 1989, 56:247-253.
20. Hadley AG, Kumpel BM, Leader KA, Poole GD, Fraser ID: Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn. Br J Haematol 1991, 77:221-228.
21. Sacks DA, Nance SJ, Garratty G, Path MRC, Petrucha RA, Horenstein J, Fotheringham N: Monocyte monolayer assay as a predictor of severity of hemolytic disease of the fetus and newborn. Am J Perinatol 1993, 10:428-431.
22. Hadley AG, Poole GD, Fraser ID: Predicting the severity of haemolytic disease of the newborn: prospective evaluation of the chemiluminescence test. Vox Sang 1992, 63:291-292.
23. Hadley AG, Kumpel BM, Leader KA, Poolet GD, Fraser ID: Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn. Br J Haematol 1991, 77:221-228.
24. Lucas GF, Hadley AG, Nance SJ, Garratty G: Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993, 33:484-487.
25. Larson PJ, Thorp JM, Miller RC, Hoffman M: The monocyte monolayer assay: a noninvasive technique for predicting the severity of in utero hemolysis. Am J Perinatol 1995, 12:157-160.
26. Dhingra Kumar N, Duguid JK, Bromilow IM: Assessment of severity of haemolylic disease of newborn by monocyte monolayer assay. Indian J Med Res 1995, 102:71-76.
27. Garner SF, Gorick BD, Lai WY, Brown D, Taverner J, Hughes-Jones NC, Contreras M, Lubenko A: Prediction of the severity of haemolytic disease of the newborn: quantitative IgG anti-D subclass determinations explain the correlation with functional assay results. Vox Sang 1995, 68:169-176.
28. Engelfriet CP, Reesink HW: Laboratory procedures for the prediction of the severity of haemolytic disease of the newborn. Vox Sang 1995, 69:61-69.
29. Filbey D, Garner SF, Hadley AG, Shepard SL: Quantitative and functional assessment of anti-RhD: a comparative study of non-invasive methods in antenatal prediction of Rh hemolytic disease. Acta Obstet Gynecol Scand 1996, 75:102-107.
30. Downing I, Bromilow IM, Templeton JG, Fraser RH: A retrospective study of red cell maternal antibodies by chemiluminescence. Vox Sang 1996, 71:226-232.
31. Hadley AG, Wilkes A, Goodrick J, Penman D, Soothill P, Lucas G: The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br J Obstet Gynaecol 1998, 105:231-234. The evaluation of the CLT for prediction of neonatal and fetal hemolysis is based on the largest number of cases. The test predicts the clinical outcome of HDN better than quantification of anti-D by AutoAnalyzer. However, whether or not the CLT can, or should, affect clinical management is not clear.
32. Moise KJ Jr, Perkins JT, Sosler SD, Brown SJ, Saade G, Carpenter RJ Jr, Thorp JA, Ludomirski A, Wilkins IA, Grannum PA: The predictive value of maternal serum testing for detection of fetal anemia in red blood cell alloimmunization. Am J Obstet Gynecol 1995, 172:1003-1009.
33. Dooren ME, Kuijpers RWAM, Joekes EC: Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR). Lancet 1992, 339:1067-1070.
34. Eichler H, Zieger W, Neppert J, Kerowgan M, Melchert F, Goldmann SF: Mild course of fetal RhD haemolytic disease due to maternal alloimmunisation to paternal HLA class I and II antigens. Vox Sang 1995, 68:243-247.
35. Shepard SL, Noble AL, Filbey D: Inhibition of the monocyte chemiluminescence response to anti-D-sensitized red cells by FcgRI-blocking antibodies which ameliorate the severity of haemolytic disease of the newborn. Vox Sang 1996, 70:157-163.
36. Flesch BK, Achtert G, Neppert J: Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for FcgRI, II and III. Ann Hematol 1997, 74:15-22.
37. Neppert J, v.Witzleben-Schurholz E, Żupańska B, Barz L, Greve O, Eichler H, Kerowgan M, Wichman MG: High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. Br J Obstet Gynaecol. In press. HLA antibodies, active in the immune inhibition test, were detected in 85.2% of mothers whose children had mild HDN comparing to 50% with severe HDN; the difference was statistically significant.
38. Watt J, Jones ML, Pepper R: Case report: significance of anti-LU8 in pregnancy. Vox Sang 1995, 68:130-131.
39. a. Transfusion 1995, 35:63-67.
40. Nance S, Scandone P, Fassl L, Miranda A, Rubino M, Sherwood W, Herman J: Monocyte monolayer assay (MMA) results are affected by transfusion of incompatible red cells. Transfusion 1997, 37:37S. It was shown that negative MMA result in the sample obtained after transfusion of incompatible red cells became positive in the sample obtained a month later.
41. Ramsey G, Sherman LA, Zimmer AM, Spies WG, Sharma L, Arndt P, Garratty G: Clinical significance of anti-At(a). Vox Sang 1995, 69:135-137.
42. b. Transfusion 1997, 37:343.
43. o phenotype in an Iranian family and management of transfusion requirements in presence of anti-Ku. Transfusion 1997, 37:36S.